Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition

Abstract

Get full access to this article

View all access options for this article.

References

Andtbacka

Kaufman

Collichio

, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788. doi:10.1200/JCO.2014.58.3377 Epub 2015 May 26. PMID: 26014293.

Chesney

Imbert-Fernandez

Telang

, et al. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Res. 2018;28(3):250-255.

Chesney

Ribas

Long

, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41(3):528-540. doi:10.1200/JCO.22.00343 Epub 2022 Aug 23. PMID: 35998300; PMCID: PMC9870217.

Dummer

Gyorki

Hyngstrom

, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27(10):1789-1796. doi:10.1038/s41591-021-01510-7 Epub 2021 Oct 4. PMID: 34608333.